Recent News

• 08.06.2026 - Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call
• 08.04.2026 - Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
• 07.15.2026 - Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
• 07.01.2026 - Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
• 06.25.2026 - Milestone Scientific Strengthens Board to Support Next Phase of Growth
• 05.27.2026 - Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
• 05.14.2026 - Milestone Scientific Reports Financial Results for First Quarter 2026
• 05.07.2026 - Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
• 05.07.2026 - Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
• 04.21.2026 - Milestone Scientific Inc. Completes $2.15 Million Private Placement

Recent Filings

• 07.31.2026 - 8-K Current report
• 07.29.2026 - 8-K Current report
• 07.29.2026 - EX-99.1 EX-99.1
• 06.25.2026 - 8-K Current report
• 06.25.2026 - EX-99.1 EX-99.1
• 06.22.2026 - DEF 14A Other definitive proxy statements
• 06.10.2026 - PRER14A Preliminary Proxy Soliciting materials
• 06.09.2026 - 424B1 Prospectus [Rule 424(b)(1)]
• 06.09.2026 - EFFECT Notice of Effectiveness
• 06.05.2026 - PRE 14A Other preliminary proxy statements